The global pre-filled syringes market is expected to grow at a moderate growth rate over the forecast period. The global pre-filled syringes market was valued at $4,663m in 2016. Visiongain forecasts this market to increase to $7,629m in 2021. The market will then continue to increase to $12,764m in 2027, growing at a CAGR of 9.7% between 2016 and 2027.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new report you find 211-page report you will receive 68 tables and 55 figures – all unavailable elsewhere.
The 211-page report provides clear detailed insight into the global pre-filled syringes market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope • Global Pre-Filled Syringes market forecasts from 2017-2027
• Pre-Filled Syringes national market forecasts from 2017-2027, covering: – United States – Japan – Germany – France – United Kingdom – Italy – Spain – Brazil – Russia – India – China
• Forecasts from 2017-2027 of the leading therapeutic sectors for the Pre-Filled Syringes market: – Insulin Therapies – Rheumatoid Arthritis (RA) Therapies – Growth Hormones – Vaccines – PCSK9 Inhibitors
• Forecasts from 2017-2027 of the leading pre-filled devices: – Lantus – NovoRapid/Novolog – Humalog – Humira – Enbrel – Norditropin – Genotropin – Praluent – Repatha
• Assessment of the leading pre-filled syringes manufacturers and related technology manufacturers
• SWOT and STEP analysis
Visiongain’s study is intended for anyone requiring commercial analyses for the Pre-Filled Syringes Market and leading companies. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1. Global Pre-Filled Syringes Market Overview 1.2. Global Pre-Filled Syringes Market Segmentation 1.3. Why You Should Read This Report 1.4. How This Report Delivers 1.5. Key Questions Answered by This Analytical Report 1.6. Who is This Report For? 1.7. Methodology 1.8. Frequently Asked Questions (FAQ) 1.9. Associated Visiongain Reports 1.10. About Visiongain
2. Introduction to Pre-Filled Syringes 2.1. What are Pre-Filled Syringes? 2.2. A Brief History of Pre-Filled Syringes 2.3. Design and Manufacture of Pre-Filled Syringes 2.3.1. Glass and Plastic Syringes 2.3.2. Safety and the Pre-Filled Syringe Market 2.3.3. Concerns over Needlestick Injuries 2.4. An Introduction to Pen Injectors and Autoinjectors 2.4.1. Pen Injectors and Autoinjectors Offer Advantages in Self-Administration 2.4.2. What Determines Injection Device Choice? 2.5. Glass versus Plastic 2.5.1. Glass 2.5.2. Plastic 2.6. Future Directions for Pre-Filled Syringes 2.7. Pre-Filled Syringes: Market Segmentation 2.8. Scope of this Report 2.8.1. Products Excluded from this Report 2.9. Currency Exchange Rates in This Report
3. Pre-Filled Syringes: World Market 2017-2027 3.1. Pre-Filled Syringes as a Share of the Global Drug Delivery Market 3.2. The World Pre-Filled Syringes Market in 2016 3.2.1. World Pre-Filled Syringes Market: Market Shares by Segment 2016 3.2.2. Leading Companies in the Pre-Filled Syringes Market 3.3. World Pre-Filled Syringes Market: Sales Forecast by Value, 2017-2027 3.4. How Will Segmental Market Shares Change to 2027? 3.5. World Pre-Filled Syringes Market: Drivers and Restraints 2017-2027 3.5.1. Biologics and Biosimilars to Drive Market Growth 3.5.2. Human Factors and Regulatory Requirements 3.5.3. Advances in Pre-Filled Syringe Manufacturing 3.5.4. Market Genericisation and Pre-Filled Syringes 3.5.5. The Injectable Drug Pipeline is Substantial 3.5.6. Competing Drug Delivery Technologies 3.6. Glass Pre-Filled Syringes Lead the Pre-Filled Syringes Market 3.6.1. Glass Pre-Filled Syringes Market: Sales Forecast by Value, 2017-2027 3.6.2. Glass Pre-Filled Syringes: Drivers and Restraints 2017-2027 3.7. Plastic Pre-Filled Syringes: Rapid Growth Forecasted 3.7.1. Plastic Pre-Filled Syringes Market: Sales Forecast by Revenue, 2017-2027 3.7.2. Plastic Pre-Filled Syringes: Drivers and Restraints 2017-2027 3.8. Pen Injectors and Autoinjectors: A Growing Segment 3.8.1. Pen Injectors and Autoinjectors Market: Sales Forecast by Value, 2017-2027 3.8.2. Pen Injectors and Autoinjectors: Drivers and Restraints 2017-2027 3.8.3. Insulin and Other Biologics to Lead Market Growth
4. Leading National and Regional Markets 2017-2027 4.1. National Breakdown of the World Pre-Filled Syringes Market 4.2. World Pre-Filled Syringes Market: National Markets Forecast 2017-2027 4.2.1. How Will National Market Shares Change to 2027? 4.3. Regional Breakdown of the World Pre-Filled Syringes Market 4.4. World Pre-Filled Syringes Market: Regional Markets Forecast 2017-2027 4.4.1. How Will Regional Market Shares Change to 2027? 4.5. US Pre-Filled Syringes Market Forecast 2017-2027 4.5.1. US Pre-Filled Syringes Market: Trends and Developments 4.5.1.1. New Drug and Device Launches to Drive Growth to 2027 4.5.1.2. The Budget Control Act 2011 and the Medical Excise Tax 4.6. Japanese Pre-Filled Syringes Market Forecast 2017-2027 4.7. EU5 Pre-Filled Syringes Market Forecast 2017-2027 4.8. Emerging Markets: Pre-Filled Syringes Market Forecast 2017-2027 4.8.1. Pre-Filled Syringe Manufacturers Are Investing in Emerging Markets 4.8.2. Chinese Pre-Filled Syringes Market Forecast 2017-2027 4.8.3. Indian Pre-Filled Syringes Market Forecast 2017-2027 4.8.4. Russian Pre-Filled Syringes Market Forecast 2017-2027 4.8.5. Brazilian Pre-Filled Syringes Market Forecast 2017-2027
5. Leading Therapeutic Sectors for Pre-Filled Syringes 2017-2027 5.1. Leading Therapeutic Sectors for Pre-Filled Syringes and Other Injection Devices in 2016 5.1.1. Vaccines and Heparins Are Major Market Sectors 5.1.2. Rising Demand in Chronic Conditions: Autoimmune Diseases and Diabetes 5.1.3. Growth for Key Market Sectors 2017-2027 5.2. Pre-Filled Syringes and Pen Injectors for Diabetes 2017-2027 5.2.1. Insulin Market Forecast 2017-2027 5.2.2. High Rates of Pen Injector Use in the EU and Japan 5.2.3. Insulin Pumps: A Technology to Challenge Pen Injectors to 2027? 5.2.4. MannKind’s Afrezza: Inhalable Insulin Approved in US 5.2.5. Injection Devices for Biosimilar Insulin Products 5.3. Rheumatoid Arthritis: Leading Biologics Dominate the Market 5.3.1. Rheumatoid Arthritis Market Forecast 2017-2027 5.3.2. All Major Injectable Therapies Are Marketed in Proprietary Devices 5.3.3. Novel Injection Systems for RA: Meeting the Needs of Patients 5.3.4. The Receding Threat from Oral Therapies to 2027 5.4. Growth Hormones: Outlook to 2027 5.4.1. Growth Hormones Market Forecast 2017-2027 5.4.2. Biosimilar Growth Hormones and Pen Injectors 5.4.3. Uptake of Needle-Free Injectors for Growth Hormones 5.5. The Vaccine Market Outlook 2017-2027 5.5.1. Vaccine Market Forecast 2017-2027 5.5.2. Single-Use Devices for Vaccine Delivery 5.5.2.1. BD Uniject: A Private-Public Collaboration 5.5.3. Needle-Free Injectors for Vaccines 5.5.4. Other Trends in Vaccine Delivery 5.6. PCSK9 Inhibitors: The Next Advance in Cholesterol-Lowering Drugs 5.6.1. PCSK9 Inhibitors Market Forecast 2017-2027 5.6.2. PCSK9 Inhibitors and Pre-Filled Syringes/Injectors
6. Leading Pre-Filled Device Therapies 2017-2027 6.1. Leading Insulin Therapies Using Pen Injectors 2017-2027 6.1.1. Lantus: The World’s Best-Selling Insulin Analogue 6.1.1.1. SoloSTAR, ClikSTAR and AllSTAR: Three Pen Injectors for Lantus 6.1.1.2. Lantus: Sales Forecast 2017-2027 6.1.2. NovoLog: The Leading Fast-Acting Insulin 6.1.2.1. NovoLog FlexPen: To Be Retired 6.1.2.2. Novo’s New FlexTouch Pen Launched 6.1.2.3. NovoLog: Sales Forecast 2017-2027 6.1.3. Humalog 6.1.3.1. Humalog: HumaPen and KwikPen 6.1.3.2. Humalog: Sales Forecast 2017-2027 6.2. Top Biologics for Rheumatoid Arthritis: Device Outlook to 2027 6.2.1. Humira: The Biggest-Selling Drug in 2015 6.2.1.1. The Humira Pen Is an Innovative Delivery Device 6.2.1.2. Humira: Sales Forecast 2017-2027 6.2.2. Enbrel: The Leading Competitor to Humira 6.2.2.1. Pre-Filled Injection Devices Available for Enbrel in 2015 6.2.2.2. Enbrel: Sales Forecast 2017-2027 6.3. Growth Hormones: Two Products Dominated the Market in 2015 6.3.1. Norditropin: the Leading Growth Hormone 6.3.1.1. Norditropin: Sales Forecast 2017-2027 6.3.2. Genotropin: Sales Forecast 2017-2027 6.4. Outlook for Leading PCSK9 Products 2017-2027 6.4.1. Praluent (alirocumab, Sanofi/Regeneron) 6.4.1.1. Praluent: Sales Forecast 2017-2027 6.4.1.2. Amgen Suit Against Sanofi/Regeneron’s Praluent 6.4.2. Repatha (evolocumab, Amgen) 6.4.2.1. Repatha: Sales Forecast 2017-2027
7. Leading Pre-Filled Syringe and Related Technology Manufacturers, 2016 7.1. Leading Pre-Filled Syringe Manufacturers market share in 2016 7.1.1. Becton, Dickinson & Company: The Market Leader 7.1.1.1. Becton, Dickinson & Company: Pre-Filled Syringes Product Portfolio 7.1.1.2. BD Historical Revenue and Market Prospects 7.1.1.3. Recent Acquisitions by BD 7.1.1.4. BD Acquisition of CareFusion 7.1.1.5. BD AutoShield Duo Pen Needle Launched in 2014 7.1.2. Gerresheimer 7.1.2.1. Gerresheimer: Pre-Filled Syringes Product Portfolio 7.1.2.2. Gerresheimer Historical Revenue 2014-2015 and Market Outlook 7.1.2.3. Gerresheimer: Expansion of Product Manufacturing Facility 7.1.2.4. Gerresheimer: Products in Development 7.1.2.5. Patent Application for Gerresheimer’s Gx G-Fix Adapter 7.1.2.6. Gerresheimer Commissioned to Manufacture Simponi Autoinjectors 7.1.2.7. Gerresheimer Opens First Development Center in China 7.1.3. Schott 7.1.3.1. Schott: Pre-Filled Syringes Product Portfolio 7.1.3.2. Schott Historical Revenue and Market Prospects 7.1.3.3. Schott: Expansion in India 7.2. Other Notable Pre-Filled Syringe Manufacturers 7.2.1. Baxter: Providing Contract Manufacturing with Pre-Filled Syringes 7.2.2. Nipro: Leading Japanese Contract Manufacturer 7.2.2.1. Nipro’s 2012 Acquisition of MGlas 7.2.3. Stevanato Group/Ompi: Insulin Vials Market Leader 7.2.4. Weigao: Pre-Filled Syringes for China and Beyond 7.2.5. Unilife: Pre-Filled Safety Syringes 7.2.6. Roselabs: Entered the Market in 2012 7.2.7. Vetter Pharma: Offering Lyo-Ject Dual-Chamber Syringes 7.2.8. Other Companies 7.3. Leading Pen Injector and Autoinjector Manufacturers in 2015 7.3.1. SHL Group 7.3.1.1. SHL Group: Pen Injectors and Autoinjectors Product Portfolio 7.3.1.2. SHL Group Market Prospects 7.3.2. Ypsomed 7.3.2.1. Ypsomed: Pen Injectors and Autoinjectors Product Portfolio 7.3.2.2. Ypsomed Historical Revenue and Market Prospects 7.3.2.3. Ypsomed: Recent Developments 7.3.3. Haselmeier 7.3.3.1. Haselmeier: Pen Injectors and Autoinjectors Product Portfolio 7.3.3.2. Haselmeier: Market Prospects 7.3.4. Owen Mumford 7.3.4.1. Owen Mumford: Pen Injectors and Autoinjectors Product Portfolio 7.3.5. Bespak: Entering the Auto-Injectors Market 7.3.6. Other Leading and Emerging Autoinjector Manufacturers 7.4. Leading Pre-Filled Syringe Component Manufacturers in 2016 7.4.1. Datwyler 7.4.1.1. Datwyler Historical Revenue and Market Prospects
8. Qualitative Analysis of the Pre-Filled Syringes Market 2017-2027 8.1. SWOT Analysis of the Pre-Filled Syringes Market 8.2. Strengths 8.2.1. Pre-Filled Syringes and Pen/Autoinjectors are Used In Chronic Conditions 8.2.2. Device Manufacturers Offer a Range of Products 8.2.3. Customisation and Product Differentiation 8.2.4. Effective Lifecycle Management 8.2.5. Advantages associated with pre-filled syringes 8.3. Weaknesses 8.3.1. Patients with Needle Phobia 8.3.2. Chronic Diseases May Make Pre-Filled Syringes Difficult to Use 8.3.3. Risk of Extractables and Leachables 8.3.4. Higher Cost and Greater Cold Chain and Storage Requirements 8.4. Opportunities 8.4.1. Biosimilars Represent a Growing Market 8.4.2. Viscous and Large-Volume Drugs Require Novel Devices 8.4.3. Technological Developments Expanding Product Portfolios 8.4.4. Many Injectable Drugs in the Pipeline 8.4.5. Growth in Emerging Markets 8.5. Threats 8.5.1. Alternative Technologies: Needle-Free and Bolus Injectors 8.5.2. New Oral Therapies for Many Chronic Conditions 8.5.3. Increasing Regulatory Barriers 8.5.4. Cost Pressures on Healthcare Payers 8.6. STEP Analysis of the Pre-Filled Syringes Market 8.6.1. Social Factors: Rising Disease Incidence and Demand for At-Home Care 8.6.2. Technological Developments: Improved Safety and Administration 8.6.3. Economic Pressures: Pre-Filled Syringes Are Cost Efficient 8.6.3.1. High Barriers to Market Entry Exist 8.6.4. Political Issues: Regulatory Developments for Pre-Filled Syringes 8.7. Regulatory and Safety Outlook for Pre-Filled Syringes, 2017-2027 8.7.1. Needlestick Safety and Prevention 8.7.2. International Regulations for Needlestick Prevention 8.7.2.1. The US: The First Country to Introduce Needlestick Legislation 8.7.2.2. The EU: New Rules from 2013 Onwards 8.7.2.3. Needlestick Safety in Japan 8.7.2.4. Legislation for Needlestick Safety in Emerging Markets 8.7.3. Manufacturers Will Continue to Develop New Devices for Needlestick Prevention 8.7.3.1. Ancillary versus Integrated Safety Devices 8.7.4. Extractables and Leachables 8.7.4.1. Companies Will Reduce Sources of Extractables and Leachables 8.7.4.2. Products that Minimise Extractables and Leachables 8.7.4.3. Protein Aggregation: The Challenge of Biological Drugs 8.7.4.4. Regulatory Requirements for Extractables and Leachables 8.8. Biologics and the Pre-Filled Syringes Market, 2017-2027 8.8.1. Manufacturing Pre-Filled Syringes for Biologics: Glass versus Plastic 8.8.2. Biologics Provide New Challenges for Device Manufacturers 8.8.2.1. Lyophilised Drugs and Dual-Chamber Devices 8.8.3. Delivery Opportunities for High Viscosity Drugs 8.8.4. Are Biosimilars an Opportunity for Pre-Filled Syringe Manufacturers? 8.9. The Role of Patients in Pre-Filled Syringe Industry Development and Growth 8.9.1. Chronic Disease Incidence 2017-2027 8.9.2. The Rise in At-Home Care 8.9.3. Improving Patient Adherence 8.9.4. Injection Devices Must be Developed for Patient Convenience: Human Factors Engineering 8.10. Technological Developments in Pre-Filled Syringes to 2027 8.10.1. Product Differentiation Will be Vital in Crowded Treatment Markets 8.10.2. Product Customisation: Adapting Injection Devices 8.10.3. Trends in Manufacturing Materials for Pre-Filled Syringes 8.10.4. Competing Technologies Will Challenge Pre-Filled Syringes 8.10.4.1. Will Needle-Free Devices Become a Significant Competing Technology? 8.10.4.2. Patients Prefer Oral Drug Delivery 8.11. Outsourcing in the Pre-Filled Syringe Industry 8.11.1. Contract Medical Device Manufacturing 8.11.2. Contract Filling of Pre-Filled Syringes
9. Conclusions 9.1. Pre-Filled Syringes and Pen/Autoinjectors: Strong Growth Expected 9.2. The World Pre-Filled Syringes Market in 2016 9.2.1. Current Leading Pre-Filled Syringes Segments 9.2.2. Leading Pre-Filled Syringes Companies 9.2.3. Leading National and Regional Markets 9.3. World Pre-Filled Syringes Market Forecast 2017-2027 9.4. The Future of the Pre-Filled Syringes Market? 9.4.1. Glass Syringes Will Continue to Dominate 9.4.2. Innovation for Growth
10. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 3.1 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Segment, 2016-2027 Table 3.2 Market Shares (%) of Leading Pre-Filled Syringes Market Segments, by Revenue, 2016, 2021 and 2027 Table 3.3 Glass Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 3.4 Selected Proprietary Polymers for Plastic Pre-Filled Syringes, 2016 Table 3.5 Plastic Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 3.6 Pen Injectors and Autoinjectors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.1 World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by National Market, 2016 Table 4.2 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 Table 4.3 Market Shares (%) of Leading National Pre-Filled Syringes Markets, 2016, 2021 and 2027 Table 4.4 World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by Regional Market, 2016 Table 4.5 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2027 Table 4.6 Market Shares of Leading Regional Pre-Filled Syringes Markets, 2016, 2021 and 2027 Table 4.7 US Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2027 Table 4.8 Japanese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.9 EU5 Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 Table 4.10 Chinese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.11 Indian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.12 Russian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.13 Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.1 Pen Manufacturing Agreements for Leading Insulin Brand Manufacturers, 2015 Table 5.2 Selected Biosimilar Insulin Pen Injectors, 2017 Table 5.3 Insulin Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.4 Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.5 Growth Hormone Therapies in Pen Injectors, 2016 Table 5.6 Growth Hormones Market Forecast: Revenues ($m), AGR and CAGR, 2016-2027 Table 5.7 Selected Biosimilar Growth Hormones in Emerging Markets, 2016 Table 5.8 Vaccines Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.9 PCSK9 Inhibitors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.1 Leading Pre-Filled Insulin Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2016 Table 6.2 Sanofi: Lantus Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.3 Novo Nordisk: NovoLog Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.4 Eli Lilly: Humalog Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.5 Leading Pre-Filled Rheumatoid Arthritis Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.6 AbbVie/Eisai: Humira Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.7 Amgen/Pfizer: Enbrel Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.8 Leading Pre-Filled Growth Hormone Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.9 Novo Nordisk: Norditropin Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.10 Pfizer: Genotropin Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.11 Sanofi: Praluent Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.12 Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.1 BD: Overview, 2016 Table 7.2 BD: Pre-Filled Injection Systems, 2016 Table 7.3 BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2010-2015 Table 7.4 Gerresheimer: Overview, 2016 Table 7.5 Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m) for 2015 and 2016, plus AGR (%) Table 7.6 Schott: Overview, 2017 Table 7.7 Schott: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 7.8 Unilife: Pre-Filled Syringe Product Portfolio, 2016 Table 7.9 Unilife: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 7.10 SHL Group: Overview, 2016 Table 7.11 SHL Group: Pen Injector and Autoinjector Portfolio, 2016 Table 7.12 Ypsomed: Overview, 2016 Table 7.13 Ypsomed: Pen Injector and Autoinjector Portfolio, 2016 Table 7.14 Ypsomed: Delivery Devices Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 7.15 Haselmeier: Overview, 2016 Table 7.16 Haselmeier: Pen Injector and Autoinjector Portfolio, 2016 Table 7.17 Owen Mumford: Overview, 2016 Table 7.18 Owen Mumford: Pen Injector and Autoinjector Portfolio, 2016 Table 7.19 Datwyler: Overview, 2016 Table 7.20 Datwyler: Pharma Packaging Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 8.1 Benefits and Weaknesses to Pre-Filled Syringes as an Injectable Delivery Device, 2017 Table 8.2 Pre-Filled Syringes Market: STEP Analysis, 2017-2027 Table 8.3 Selected Safety Products for Pre-Filled Syringes, 2016 Table 8.4 Selected Pre-Filled Injection Devices for Lyophilised Drugs, 2016 Table 8.5 Pre-Filled Syringe Manufacturers: Alternative Injectable Technologies, 2016 Table 8.6 Selected Insulin Pumps Available, 2016 Table 8.7 Oral Drug Competitors for Leading Pre-Filled Syringe Therapeutic Sectors, 2017-2027 Table 8.8 Selected Leading CMOs: Pre-Filled Syringe Filling Capabilities, 2016
List of Figures Figure 1.1 Global Pre-Filled Syringes Market Segmentation Overview, 2017 Figure 2.1 Diagram of Syringe Parts Figure 2.2 Timeline of Pre-Filled Syringe Development, 1950-2015 Figure 2.3 Major Trends for Pre-Filled Syringe Market Growth, 2017 Figure 3.1 World Pre-Filled Syringes Market: Market Shares (%) by Segment, 2016 Figure 3.2 World Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 3.3 World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2016 Figure 3.4 World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2021 Figure 3.5 World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2027 Figure 3.6 World Pre-Filled Syringes Market: Drivers and Restraints, 2017-2027 Figure 3.7 Glass Pre-Filled Syringes Market Forecast: Revenues ($m), 2016-2027 Figure 3.8 Glass Pre-Filled Syringes Market: Drivers and Restraints, 2017-2027 Figure 3.9 Plastic Pre-Filled Syringes Market Forecast: Revenues ($m), 2016-2027 Figure 3.10 Plastic Pre-Filled Syringes Market: Drivers and Restraints, 2017-2027 Figure 3.11 Pen Injectors and Autoinjectors Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 3.12 Pen Injectors and Autoinjectors Market: Drivers and Restraints, 2017-2027 Figure 4.1 World Pre-Filled Syringes Market: Revenues ($m) by National Market, 2016 Figure 4.2 World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2016 Figure 4.3 World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2021 Figure 4.4 World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2027 Figure 4.5 World Pre-Filled Syringes Market: Revenues ($m) by Regional Market, 2016 Figure 4.6 World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2016 Figure 4.7 World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2021 Figure 4.8 World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2027 Figure 4.9 US Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.10 Japanese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.11 EU5 Pre-Filled Syringes Market Forecast: Revenues ($m) by National Market, 2016-2027 Figure 4.12 Chinese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.13 Indian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.14 Russian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.15 Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.1 Insulin Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.2 Rheumatoid Arthritis Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.3 Growth Hormones Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.4 Vaccines Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.5 PCSK9 Inhibitors Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.1 Sanofi: Lantus Revenue ($m) and AGR (%), 2016-2027 Figure 6.2 Novo Nordisk: NovoLog Revenue ($m) and AGR (%), 2016-2027 Figure 6.3 Eli Lilly: Humalog Revenue ($m) and AGR (%), 2016-2027 Figure 6.4 AbbVie/Eisai: Humira Revenue ($m) and AGR (%), 2016-2027 Figure 6.5 Amgen/Pfizer: Enbrel Revenue ($m) and AGR (%), 2016-2027 Figure 6.6 Novo Nordisk: Norditropin Revenue ($m) and AGR (%), 2016-2027 Figure 6.7 Pfizer: Genotropin Revenue ($m) and AGR (%), 2016-2027 Figure 6.8 Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2016-2027 Figure 6.9 Amgen: Repatha Revenue ($m) and AGR (%), 2016-2027 Figure 7.1 Global Pre-filled syringes market market share in 2016 Figure 7.2 BD: Pharmaceutical Systems Revenue ($m), AGR (%), 2010-2015 Figure 7.3 Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m), 2015 and 2016 Figure 7.4 Schott: Net Revenue ($m) and AGR (%), 2010-2015 Figure 7.5 Unilife: Net Revenue ($m) and AGR (%), 2010-2015 Figure 7.6 Ypsomed: Delivery Devices Revenue ($m) and AGR (%), 2010-2015 Figure 7.7 Datwyler: Pharma Packaging Revenue ($m) and AGR (%), 2010-2015 Figure 8.1 Pre-Filled Syringes Market: Strengths and Weaknesses, 2017-2027 Figure 8.2 Pre-Filled Syringes Market: Opportunities and Threats, 2017-2027 Figure 9.1 World Pre-Filled Syringes Market Forecast: Revenues ($m) by Segment, 2016-2027
AbbVie Ache Amega Biotech Amgen Antares Pharma Aptar Stelmi AstraZeneca Baxter International Becton, Dickinson and Company Bespak Biocon Bioject Medical Technologies Biomarin Biosidus Boehringer Ingelheim Bristol-Myers Squibb Cambridge Consultants CareFusion Corporation Celgene Centocor Daikyo Seiko Datwyler Dong-A Dr. Reddy’s Eisai Pharmaceutical Eli Lilly Ferring Gan & Lee GeneScience Pharmaceuticals Gerresheimer GlaxoSmithKline Haselmeier Helvoet Pharmaceutical Hospira Incepta Pharmaceuticals Janssen Biotech Johnson and Johnson LG Life Sciences/Biopartners Mannkind Merck & Co Merck Serono Mitsubishi Tanabe Nektar Therapeutics Nipro Novartis Novo Nordisk OPKO Health Oval Medical Owen Mumford PA Consulting Group Palatin Technologies Pfizer PharmaJet Pharmstandard Polfa Tarchomin Regeneron Rhone Poulenc-Rorer Roehr Products Roselabs Bioscience Samsung Bioepis Sandoz Sanofi Schott Schott Kaisha Schott Xinkang Pharmaceutical Packaging SciGen Shanghai Celgen Bio-Pharmaceutical Shanghai CP Guojin SHL Group Square Pharmaceuticals Stevanato Group (Ompi) Takeda Pharmaceutical Terumo Teva Pharmaceutical Tonghua Dongbao UCB Unlife Vetter Vetter Pharma Weigao West Pharmaceuticals Wockhardt Ypsomed Zeon
Organisations Mentioned in the Report Battele Memorial Institute Carl Zeiss Foundation Centers for Disease Control (US) European Society of Cardiology National Health Service (UK) Parenteral Drug Association PATH UNICEF US Agency for International Development US Federal Drug Administration World Health Organization
Download sample pages
Complete the form below to download your free sample pages for Global Pre-Filled Syringes Market Forecast 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
